Preference for pharmaceutical formulation and treatment process attributes

by Stewart KD, Johnston JA, Matza LS, Curtis SE, Havel HA, Sweetana SA, Gelhorn HL
Published 2016-07-01

Health state utilities associated with adult attention-deficit/hyperactivity disorder

by Matza LS, Devine MK, Haynes VS, Davies EW, Kostelec JM, Televantou F, Jordan JB
Published 2014-07-01

Patient-Reported Outcomes and Impact of Type 2 Diabetes: A Cross-Sectional Study in the Kingdom of Saudi Arabia

by Gelhorn HL, Boye KS, Shalhoub H, Matza LS, Jordan JB, Alhammad A, Anand SB, Ekhzaimy AA, Strizek A
Published 2020-11-01

Utilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastases

by Matza LS, Cong Z, Chung K, Stopeck A, Tonkin K, Brown J, Braun A, Van Brunt K, McDaniel K
Published 2013-08-01

Patient preferences in Italy: health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes

by Matza LS, Boye KS, Jordan JB, Norrbacka K, Gentilella R, Tiebout AR, Browne C, Orsini Federici M, Biricolti G, Stewart KD
Published 2018-06-01

Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation

by Matza LS, Phillips GA, Revicki DA, Ascher-Svanum H, Malley KG, Palsgrove AC, Faries DE, Stauffer V, Kinon BJ, Awad AG, Keefe RS, Naber D
Published 2012-07-01